How do you approach imaging in patients with M0 castration-resistant prostate cancer with rising PSA on an ARSI?

I do not use molecular imaging (e.g., PSMA-PET/CT) for patients with CRPC (including both mCRPC and nmCRPC) except as a screening tool for Pluvicto eligibility for three reasons.

1. Most patients have metastasis already. In one study that used molecular imaging in patients with nmCRPC, they identified ...